CIPLA DEFERASIROX deferasirox 90 mg tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla deferasirox deferasirox 90 mg tablet blister pack

cipla australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; poloxamer; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. [invented name] is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. [invented name] is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.

CIPLA TADALAFIL 2.5 tadalafil 2.5 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla tadalafil 2.5 tadalafil 2.5 mg film-coated tablet blister pack

cipla australia pty ltd - tadalafil, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

CIPLA TADALAFIL 10  tadalafil 10 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla tadalafil 10 tadalafil 10 mg film-coated tablet blister pack

cipla australia pty ltd - tadalafil, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; sodium lauryl sulfate; lactose monohydrate; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

CIPLA TADALAFIL 5 tadalafil 5 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla tadalafil 5 tadalafil 5 mg film-coated tablet blister pack

cipla australia pty ltd - tadalafil, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; hyprolose; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

CIPLA TADALAFIL 20 tadalafil 20 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla tadalafil 20 tadalafil 20 mg film-coated tablet blister pack

cipla australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; hyprolose; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

CIPLA LINEZOLID linezolid 600 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla linezolid linezolid 600 mg film-coated tablet blister pack

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; sodium starch glycollate type a; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - cipla linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,cipla linezolid is active against gram-positive bacteria only. ,cipla linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

CIPLA ENTECAVIR entecavir (as monohydrate) 0.5 mg film coated tablets ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla entecavir entecavir (as monohydrate) 0.5 mg film coated tablets

cipla australia pty ltd - entecavir monohydrate, quantity: 0.532 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; crospovidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - cipla entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

CIPLA ENTECAVIR entecavir (as monohydrate) 1mg film coated tablets ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla entecavir entecavir (as monohydrate) 1mg film coated tablets

cipla australia pty ltd - entecavir monohydrate, quantity: 1.064 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; hyprolose; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - cipla entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

CIPLA DONEPEZIL donepezil hydrochloride (as monohydrate) 5 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla donepezil donepezil hydrochloride (as monohydrate) 5 mg film-coated tablet blister pack

cipla australia pty ltd - donepezil hydrochloride monohydrate, quantity: 5.21 mg (equivalent: donepezil hydrochloride, qty 5.21 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - cipla donepezil (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer's disease.

CIPLA DONEPEZIL donepezil hydrochloride (as monohydrate) 10 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

cipla donepezil donepezil hydrochloride (as monohydrate) 10 mg film-coated tablet blister pack

cipla australia pty ltd - donepezil hydrochloride monohydrate, quantity: 10.43 mg (equivalent: donepezil hydrochloride, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; lactose monohydrate; maize starch; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000 - cipla donepezil (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer's disease.